Robert Ticktin
Geschäftsführer bei PMV PHARMACEUTICALS, INC.
Profil
Robert Ticktin is currently the Head of Operations & General Counsel at PMV Pharmaceuticals, Inc. He previously worked as the Associate Corporate General Counsel at Tesaro, Inc., the Senior Vice President & General Counsel at Zalicus, Inc., and the Senior Vice President & General Counsel at EPIRUS Biopharmaceuticals, Inc. He also served as the Secretary, Senior Vice President & General Counsel at EPIRUS Biopharmaceuticals, Inc. Mr. Ticktin completed his undergraduate degree at The Ohio State University and his graduate degree at Fordham University School of Law.
Aktive Positionen von Robert Ticktin
| Unternehmen | Position | Beginn |
|---|---|---|
| PMV PHARMACEUTICALS, INC. | Geschäftsführer | - |
Ehemalige bekannte Positionen von Robert Ticktin
| Unternehmen | Position | Ende |
|---|---|---|
| TESARO INC | Corporate Officer/Principal | - |
EPIRUS Biopharmaceuticals, Inc. /Old/
 EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | General Counsel | - |
| EPIRUS BIOPHARMACEUTICALS, INC. | General Counsel | - |
Zalicus, Inc.
 Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | General Counsel | - |
Ausbildung von Robert Ticktin
| The Ohio State University | Undergraduate Degree |
| Fordham University School of Law | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| EPIRUS BIOPHARMACEUTICALS, INC. | Health Technology |
| PMV PHARMACEUTICALS, INC. | Commercial Services |
| Private Unternehmen | 3 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
EPIRUS Biopharmaceuticals, Inc. /Old/
EPIRUS Biopharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA. | Health Technology |
Zalicus, Inc.
Zalicus, Inc. Pharmaceuticals: MajorHealth Technology Zalicus, Inc. is a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain. The company develops Z944, a novel oral T-type calcium channel blocker that has completed Phase Ib clinical studies for the treatment of pain indications. It is also engaged in research and preclinical development activities on its selective ion channel modulators targeting the Nav1.7 sodium channel for the treatment of pain. The company changed its name from CombinatoRx, Inc. to Zalicus, Inc. on September 8, 2010. Zalicus was founded on March 28, 2000 and is headquartered in Cambridge, MA. | Health Technology |
